Linagliptin Stada (Linagliptin)

Linagliptin is a DPP‑4 inhibitor used to improve glycaemic control in type 2 diabetes mellitus.

• Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
• Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction when metformin alone is insufficient.
• Type 2 diabetes mellitus (combined with other oral agents): offers further glucose control as part of multi‑drug regimens.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, resulting in improved post‑prandial and fasting blood glucose regulation without causing hypoglycaemia when used alone.

Common Side Effects

• Nasopharyngitis: mild upper respiratory infection symptoms.
• Headache: transient mild to moderate pain.
• Upper respiratory tract infection: cough, sore throat, or congestion.
• Dizziness: occasional light‑headedness.
• Gastrointestinal discomfort: nausea or abdominal pain.
• Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with vomiting.
• Severe allergic reactions: angioedema, anaphylaxis, or rash.
• Hepatic injury: elevated liver enzymes or jaundice.
• Stevens‑Johnson syndrome: serious skin blistering.
• Severe hypoglycaemia: when combined with insulin or sulfonylureas.
• Acute renal failure: rare but reported in susceptible patients.

Linagliptin should be used with clinical monitoring and awareness of patient‑specific factors.

• Renal function assessment: evaluate eGFR before initiating therapy.
• Hepatic function monitoring: check liver enzymes periodically.
• Cardiovascular disease: use caution in patients with unstable heart conditions.
• Combination with sulfonylureas or insulin: monitor for hypoglycaemia.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concomitant use with insulin: increased risk of severe hypoglycaemia.
• Duplicate DPP‑4 inhibition (other DPP‑4 inhibitors): may cause excessive pharmacologic effect.
• Strong P‑gp inhibitors (e.g., itraconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely)

• Metformin: monitor renal function and lactic acidosis risk.
• Rifampin: may reduce linagliptin exposure, consider dose adjustment.
• Diuretics: watch for electrolyte disturbances.
• ACE inhibitors: monitor blood pressure and renal parameters.
• NSAIDs: assess for potential renal impairment.